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Diversification in
Salmonella
Typhimurium DT104
To the Editor: Multidrug-resistant
(MDR)  Salmonella  Typhimurium
definitive phage type (DT) 104 with
chromosomally encoded resistance to
ampicillin, chloramphenicol, strepto-
mycin/spectinomycin, sulfonamides,
and tetracyclines (ACSSpSuT) was
first identified and characterized in
the United Kingdom in the early
1990s (1). MDR DT104 has subse-
quently caused numerous outbreaks
throughout the world (1). The organ-
ism is characterized by a distinctive
Xba  I-generated pulsed-field profile
(PFP), designated Xtm 1 (2), carriage
of the 90-kb S. Typhimurium serovar-
specific plasmid (SSP), and presence
of the 43-kb Salmonella genomic
island 1 (SGI 1), which is composed
of integrons containing, respectively,
the ASu (blaCARB-2 and sul1) and SSp
(aadA2) genes, with intervening plas-
mid-derived genes coding for chlo-
ramphenicol/florfenicol (cmlA) and
tetracycline resistance (tetG) (1,3,4).
The same genetic characteristics have
been observed in MDR strains of the
closely related DTs 12 and 104b (5)
and in some strains of phage type
U302 (4). All isolates of MDR DT104
ACSSpSuT contain the same gene
cassettes irrespective of source or
country of origin. Although MDR
DT104 has declined during the last 5
years, the organism remains the most
common MDR Salmonella in the
United Kingdom and many other
European countries (6).
Since 1998, MDR DT104 has
undergone changes in both resistance
spectrum and genetic structure. In the
United Kingdom, outbreaks of MDR
DT104 have been caused by new sub-
clones with additional resistance to
trimethoprim (Tm) (R-type ACSSpSu
TTm) (7), by clones with decreased
susceptibility to ciprofloxacin (CpL)
(R-type ACSSpSuTCpL) (1), and by
strains of R-type SSpSu. In 2002, an
outbreak of MDR DT104
ACSSpSuTTm with >200 cases was
recognized (7). The outbreak strain
was characterized by 3 plasmids of
6.8, 3.0, and 1.5 kb. The 6.8-kb plas-
mid coded for resistance to sulfon-
amides and trimethoprim, with
trimethoprim resistance being mediat-
ed by dhfr1b. The outbreak strain
lacked the S. Typhimurium SSP and
was negative by polymerase chain
reaction (PCR) for a 437-bp internal
fragment of the Salmonella plasmid
virulence (spv)C gene. The absence of
the SSP was reflected in the PFP,
which was identical to Xtm 1 but
lacked a fragment of ≈90 kb that cor-
responds to the presence of the SSP
(4). Astrain of R-type ACSSpSuT that
also lacked the SSP and with a PFP
indistinguishable from that of the
ACSSpSuTTm strain caused a simul-
taneous outbreak with >40 cases (7).
This strain was also characterized by
2 plasmids of 3.0 and 1.5 kb but did
not possess the 6.8-kb sulfonamide-
trimethoprim resistance plasmid.
Decreased susceptibility to
ciprofloxacin coupled with resistance
to nalidixic acid (Nx) was first report-
ed in MDR DT104 in 1996 in the
United Kingdom (1). Four mutations
in gyrA, each giving rise to resistance
to Nx/CpL, were subsequently identi-
fied in MDR DT104. The most com-
mon mutation was aspartate (Asp)-87
to asparagine (AAC) and involved a
change from aspartate (GAC) to
AAC. An identical mutation was iden-
tified in a MDR DT104 strain respon-
sible for an outbreak in Denmark in
1998 (8). In 1999, an Asp-87 to
glycine mutation was identified in a
CpL MDR DT104 strain responsible
for a major outbreak in northwestern
England (1). Subsequently, >500 spo-
radic MDR DT104 infections in the
United Kingdom have involved
strains with CpL.
In 2004, 2 simultaneous outbreaks
of DT104 were recorded in the United
Kingdom in which the strains were of
R-type SSpSu, 1 involving >100 cases
and 1 involving >50 cases. Isolates
were characterized by pulsed-field gel
electrophoresis coupled with plasmid
profile analysis. Resistance genes
were identified by using PCR with
primers specific for blaTEM  (A),
blaCARB-2, cmlA, catI (C), catIII (C),
aadA2, sul1, and tetG (4). Testing for
SGI1 was conducted by using primers
U7-L12 and LJ-R1 for the left junc-
tion and primers 104-RJ and 104-D
for the right junction (9). All isolates
exhibited the Xtm 1 PFP, but strains
from the 2 outbreaks could be differ-
entiated by the presence or absence of
an additional plasmid of ≈3 kb. By
using PCR, all isolates possessed
aadA2 and sul1 but were negative for
blaTEM, blaCARB-2, cmlA, catI, catIII,
and tetG. Similarly, all strains were
positive for the left junction of SGI1.
These results indicate that the SGI1
was in the same chromosomal loca-
tion as for DT104 ACSSpSuT but was
lacking the right junction.
These findings demonstrate that
evolutionary changes have occurred
involving both loss and acquisition of
drug resistance genes, the develop-
ment of chromosomal mutations con-
ferring resistance to Nx/CpL, and in
certain subclones, the loss of the SSP.
None of these changes has altered the
virulence of the organism, with blood-
stream invasion in only 1.6% of 408
cases in the United Kingdom. These
findings contrast with those in the
United States, where MDR nonty-
phoidal Salmonella have been associ-
ated with excessive numbers of
bloodstream infections (10). 
All facets of the organism should
be explored for epidemiologic investi-
gations. These should include phage
type, antibiogram, plasmid profile,
and PFP, coupled with the identifica-
tion of resistance genes and integrons,
and, when appropriate, the characteri-
zation of mutations conferring resist-
ance to quinolone antimicrobial
agents. 
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Extended-spectrum
β β-Lactamase-
producing Flora in
Healthy Persons 
To the Editor: Extended-spectrum
β-lactamase (ESBL)–producing
gram-negative bacilli are endemic in
hospitals. In intensive care units, 2%
prevalence of ESBL-producing
organisms has been reported (1).
Exceedingly high rates of ESBL-pro-
ducing bacteria in Indian hospitals
prompted us to look at the fecal car-
riage of ESBL in the community (2).
One hundred healthy executives
received a comprehensive health
check at our tertiary care center in
central Mumbai from August to
September 2004. The predominant
isolates from stool samples obtained
for routine examination were cul-
tured, and initial screening for ESBL
production was conducted by using
the disk diffusion method according
to NCCLS guidelines (3). For these
isolates, the ESBL phenotypic confir-
mation was performed with cef-
tazidime-clavulanate for an increase
in zone diameter by 5 mm (disk
potentiation). In addition, the ATB
BLSE strip (bioMérieux, Lyon,
France) was used to confirm the pres-
ence of inhibitor (sulbactam)-suscep-
tible enzymes and to differentiate the
strains from those that were either
inhibitor resistant or harboring other
β-lactamases, such as those of AmpC
derivation. The ATB BLSE strip con-
sists of a varying concentration of cef-
tazidime, 0.5–32 mg/L, and aztreon-
am, 0.5–8 mg/L, with varying combi-
nations of these agents with a β-lacta-
mase inhibitor, i.e., + sulbactam,
0.06–1 mg/L. Cefotetan (4 and 32
mg/L) and imipenem (4 and 8 mg/L)
were also included in the strip. The
test was considered positive when a
variation of >4 dilutions was observed
between the antimicrobial agent test-
ed alone and the agent combined with
the inhibitor. Eleven of the 100 sam-
ples screened were positive for
ESBL-producing Escherichia coli and
Klebsiella pneumoniae. Seven of the
11 were confirmed by using the ATB
BLSE strip. The MIC of ceftazidime
and aztreonam in all 7 isolates was
8 µg/mL. We might be underreporting
ESBL producers in these cases by not
including the cefotaxime-clavulanate
combination in addition to the cef-
tazidime-clavulanate concentration.
The percentage resistance to
ciprofloxacin was 45%. All isolates
were susceptible to amikacin and the
carbapenems. None of the executives
gave a history of hospitalization in the
last year or history of antimicrobial
drug consumption in the last 6
months.
This trend in patients with no
apparent risk factors for ESBL car-
riage calls for urgent attention.
Unknown environmental factors are
likely playing a key role in maintain-
ing this selective pressure. Larger
studies are required to substantiate
these findings. 
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